Although it is the effects of O-GlcNAcylated RACK1 on the NLRP3 inflammasome that are thought to underlie its regulation of tumours, tumour microenvironment and immune therapy response [150], the interactions of O-GlcNAcylated RACK1 on circadian, YY1, PP2A, acetyl-CoA and the melatonergic pathway may better integrate the effects of RACK1 with other tumour regulatory factors and processes, including metabolic. Here, YY1 is linked to neoplasm.